Peptide-based glioma-targeted drug delivery vector gHoPe2

Bioconjugate Chemistry

Volumn 24, Issue 3, 2013, Pages 305-313

  Eriste, Elo ^a   Kurrikoff, Kaido ^a   Suhorutšenko, Julia ^a   Oskolkov, Nikita ^a   Copolovici, Dana Maria ^a   Jones, Sarah ^b   Laakkonen, Pirjo ^c,d   Howl, John ^b   Langel, Ülo ^a,e  

^a UNIVERSITY OF TARTU   (Estonia)

^b UNIVERSITY OF WOLVERHAMPTON   (United Kingdom)

^c UNIVERSITY OF HELSINKI   (Finland)

^d Foundation for the Finnish Cancer Institute   (Finland)

^e STOCKHOLM UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOTHERAPY; CONTROLLED DRUG DELIVERY; DIAGNOSIS; FLUORESCENCE; MAMMALS; PEPTIDES; TARGETED DRUG DELIVERY; VECTORS;

'CURRENT; BRAIN TUMORS; CELL-PENETRATING PEPTIDE; DELIVERY VECTOR; DOXORUBICIN; DRUG DELIVERY STRATEGIES; FLUORESCENT MARKERS; HOMING PEPTIDE; IN-VITRO; PATIENT PROGNOSIS;

TUMORS;

CELL PENETRATING PEPTIDE; DOXORUBICIN; GHO PEPTIDE; GHOPE2 PEPTIDE; GHOPE3 PEPTIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER SIZE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG TARGETING; DRUG UPTAKE; FLOW CYTOMETRY; GENE VECTOR; GLIOMA; GLIOMA CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTERNALIZATION; MEMBRANE BINDING; MOUSE; NONHUMAN; PEPTIDE SYNTHESIS; PEPTIDE VECTOR; PHAGE DISPLAY; PROTEIN BINDING; PROTEIN STRUCTURE; SURVIVAL; WEIGHT REDUCTION;

EID: 84875451385     PISSN: 10431802     EISSN: 15204812     Source Type: Journal    
DOI: 10.1021/bc300370w     Document Type: Article

References (20)

1. Kratz, F., Senter, P., and Steinhagen, H. (2012) Drug Delivery in Oncology: From Basic Research to Cancer Therapy, Wiley-VCH Verlag GmbH & Co. KGaA.
2. Ohgaki, H. and Kleihues, P. (2005) Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas J. Neuropathol. Exp. Neurol. 64, 479-89
3. Siegal, T., Horowitz, A., and Gabizon, A. (1995) Doxorubicin encapsulated in sterically stabilized liposomes for the treatment of a brain tumor model: biodistribution and therapeutic efficacy J. Neurosurg. 83, 1029-1037
4. Kurrikoff, K., Suhorutšenko, J., and Langel, Ü. (2012) Cell-Penetrating Peptides in Cancer Targeting, in Drug Delivery in Oncology: From Basic Research to Cancer Therapy (Kratz, F., Senter, P., and Steinhagen, H., Eds.) pp 1189-1217, Wiley-VCH Verlag GmbH & Co. KGaA.
5. Pasqualini, R., Koivunen, E., and Ruoslahti, E. (1997) Alpha v integrins as receptors for tumor targeting by circulating ligands Nat. Biotechnol. 15, 542-6
6. Essler, M. and Ruoslahti, E. (2002) Molecular specialization of breast vasculature: A breast-homing phage-displayed peptide binds to aminopeptidase P in breast vasculature Proc. Natl. Acad. Sci. U.S.A. 99, 2252-2257
7. Myrberg, H., Zhang, L. L., Mäe, M., and Langel, Ü. (2008) Design of a tumor-homing cell-penetrating peptide Bioconjugate Chem. 19, 70-75
8. Langel, Ü. (2011) Cell-Penetrating Peptides. Methods and Protocols. Methods in Molecular Biology, p 683, Humana Press.
9. Ezzat, K., El Andaloussi, S., Abdo, R., and Langel, Ü. (2010) Peptide-based matrices as drug delivery vehicles Curr. Pharm. Des. 16, 1167-1178
10. El-Andaloussi, S., Holm, T., and Langel, Ü. (2005) Cell-penetrating peptides: mechanisms and applications Curr. Pharm. Des. 11, 3597-611
11. Elmquist, A., Lindgren, M., Bartfai, T., and Langel, Ü. (2001) VE-cadherin-derived cell-penetrating peptide, pVEC, with carrier functions Exp. Cell Res. 269, 237-44
12. Lundin, P., Johansson, H., Guterstam, P., Holm, T., Hansen, M., Langel, Ü., and EL Andaloussi, S. (2008) Distinct uptake routes of cell-penetrating peptide conjugates Bioconjugate Chem. 19, 2535-42
13. Elmquist, A., Hansen, M., and Langel, Ü. (2006) Structure-activity relationship study of the cell-penetrating peptide pVEC Biochim. Biophys. Acta 1758, 721-9
14. Fields, G. B. and Noble, R. L. (1990) Solid phase peptide synthesis utilizing 9-fluorenylmethoxycarbonyl amino acids Int. J. Pept. Protein Res. 35, 161-214
15. Liang, J. F. and Yang, V. C. (2005) Synthesis of doxorubicin-peptide conjugate with multidrug resistant tumor cell killing activity Bioorg. Med. Chem. Lett. 15, 5071-5
16. Simberg, D., Duza, T., Park, J. H., Essler, M., Pilch, J., Zhang, L. L., Derfus, A. M., Yang, M., Hoffman, R. M., Bhatia, S., Sailor, M. J., and Ruoslahti, E. (2007) Biomimetic amplification of nanoparticle homing to tumors Proc. Natl. Acad. Sci. U.S.A. 104, 932-936
17. Laakkonen, P., Akerman, M. E., Biliran, H., Yang, M., Ferrer, F., Karpanen, T., Hoffman, R. M., and Ruoslahti, E. (2004) Antitumor activity of a homing peptide that targets tumor lymphatics and tumor cells Proc. Natl. Acad. Sci. U.S.A. 101, 9381-9386
18. Agemy, L., Friedmann-Morvinski, D., Kotamraju, V. R., Roth, L., Sugahara, K. N., Girard, O. M., Mattrey, R. F., Verma, I. M., and Ruoslahti, E. (2011) Targeted nanoparticle enhanced proapoptotic peptide as potential therapy for glioblastoma Proc. Natl. Acad. Sci. U. S. A. 108, 17450-5
19. Rousselle, C., Clair, P., Lefauconnier, J. M., Kaczorek, M., Scherrmann, J. M., and Temsamani, J. (2000) New advances in the transport of doxorubicin through the blood-brain barrier by a peptide vector-mediated strategy Mol. Pharmacol. 57, 679-686
20. Mäe, M., Myrberg, H., El-Andaloussi, S., and Langel, Ü. (2009) Design of a tumor homing cell-penetrating peptide for drug delivery International Journal of Peptide Research and Therapeutics 15, 11-15